AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34314856 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of home‐delivered medically tailored meals (MTM)
Number of subjects: 600
Study 34314856 — intervention group
Group type: EXPERIMENTAL
Intervention: MTM + 12 months of telehealth‐delivered medical nutrition therapy (tele‐MNT)
Number of subjects: 600
Study 34314856 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600
Study 34314856 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 600
Study 34314856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of the intervention
Number of subjects: 600
Study 35564908 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga programme for T2DM prevention (YOGA-DP)
Number of subjects: 25
Study 35564908 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 25
Study 33185896 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (1.2 mg kg–1 oral dose)
Number of subjects: 25
Study 34622548 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (3, 7 or 14 mg)
Number of subjects: 701
Study 34622548 — intervention group
Group type: COMPARATOR
Intervention: Comparator (placebo or once‐daily subcutaneous liraglutide 0.9 mg [PIONEER 9]; once‐weekly subcutaneous dulaglutide 0.75 mg [PIONEER 10])
Number of subjects: 701
Study 32246414 — intervention group
Group type: EXPERIMENTAL
Intervention: OAGB after LAGB
Number of subjects: 57
Study 36030327 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron followed by daily doses for five days
Number of subjects: 90
Study 36030327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 34382412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus ifosfamide and etoposide
Number of subjects: 0
Study 34382412 — intervention group
Group type: COMPARATOR
Intervention: Ifosfamide plus etoposide
Number of subjects: 0
Study 36027576 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-based mobile app (ICE-TI)
Number of subjects: 38
Study 36027576 — intervention group
Group type: COMPARATOR
Intervention: Independent study control group
Number of subjects: 38
Study 33652093 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice representatives reporting on medication shortages
Number of subjects: 600
Study 33652093 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice representatives reporting on missing opioid medications
Number of subjects: 600
Study 33652093 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice representatives reporting on disposal practices
Number of subjects: 600
Study 35588970 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid phenotypic antibiotic susceptibility testing (AST) with antimicrobial stewardship programmes (ASP)
Number of subjects: 116
Study 35588970 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid phenotypic AST
Number of subjects: 116
Study 35689274 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation for 8 weeks
Number of subjects: 0
Study 35689274 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation for 8 weeks
Number of subjects: 0
Study 35689274 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 0
Study 32934343 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary biomarker panel combining uTFF1, uADAM12, and H. pylori
Number of subjects: 282
Study 32934343 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary biomarker panel for stage I GC
Number of subjects: 282
Study 34914696 — intervention group
Group type: EXPERIMENTAL
Intervention: 3HP facilitated directly observed therapy (DOT)
Number of subjects: 684
Study 34914696 — intervention group
Group type: EXPERIMENTAL
Intervention: 3HP facilitated self-administered therapy (SAT)
Number of subjects: 684
Study 34914696 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed choice between DOT and SAT using a shared decision-making aid
Number of subjects: 684
Study 34914696 — intervention group
Group type: EXPERIMENTAL
Intervention: 3HP delivery strategies (aggregate outcome)
Number of subjects: 684
Study 33395691 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular Activity Breaks
Number of subjects: 18
Study 33395691 — intervention group
Group type: COMPARATOR
Intervention: Prolonged Sitting
Number of subjects: 18
Study 33395691 — intervention group
Group type: COMPARATOR
Intervention: Prolonged Standing
Number of subjects: 18
Study 35177302 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (100 µg, two doses, intramuscular injections 28 days apart)
Number of subjects: 200
Study 35177302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 33766713 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with CCTα biomarker
Number of subjects: 250
Study 33766713 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with CCTα and emmprin biomarkers
Number of subjects: 250
Study 33766713 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with CCTα, survivin, or BCL‐2 biomarkers
Number of subjects: 250
Study 33766713 — intervention group
Group type: COMPARATOR
Intervention: No neoadjuvant chemotherapy (no-NAC)
Number of subjects: 250
Study 33204076 — intervention group
Group type: EXPERIMENTAL
Intervention: XueBiJing (XBJ) injection, 100 mL, q 12 h for 5-7 days
Number of subjects: 291
Study 33204076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 35489749 — intervention group
Group type: EXPERIMENTAL
Intervention: S-PCI ≥ 18.5
Number of subjects: 118
Study 35489749 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-PCI
Number of subjects: 118
Study 35489749 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual disease (RD) of any size
Number of subjects: 118
Study 35489749 — intervention group
Group type: EXPERIMENTAL
Intervention: S-PCI
Number of subjects: 118
Study 35489749 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI > 18.5
Number of subjects: 118
Study 33615901 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic quadriceps stretching exercises
Number of subjects: 44
Study 33615901 — intervention group
Group type: COMPARATOR
Intervention: Static quadriceps stretching exercises
Number of subjects: 44
Study 32731981 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme hydrolysate gross energy (EHGE) in mixed diets
Number of subjects: 384
Study 32731981 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme hydrolysate gross energy (EHGE) in experimental diets
Number of subjects: 384
Study 32731981 — intervention group
Group type: EXPERIMENTAL
Intervention: EHGE requirement for ducks from hatch to 21 days of age
Number of subjects: 384
Study 36396068 — intervention group
Group type: EXPERIMENTAL
Intervention: AIM2ACT mobile health intervention (n = 80)
Number of subjects: 160
Study 36396068 — intervention group
Group type: COMPARATOR
Intervention: mHealth attention control condition (n = 80)
Number of subjects: 160
Study 33129818 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 403
Study 33129818 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKAs)
Number of subjects: 403
Study 35139723 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural correction exercises
Number of subjects: 72
Study 35139723 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal mobilization
Number of subjects: 72
Study 35139723 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 32193775 — intervention group
Group type: EXPERIMENTAL
Intervention: I-F (Cryoablation with CPVI and additional substrate modification by radiofrequency ablation)
Number of subjects: 90
Study 32193775 — intervention group
Group type: COMPARATOR
Intervention: RF (Radiofrequency ablation with CPVI and additional substrate modification)
Number of subjects: 90
Study 33139537 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous BFKB8488A injection
Number of subjects: 0
Study 33139537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34417396 — intervention group
Group type: EXPERIMENTAL
Intervention: 40U DaxibotulinumtoxinA (DAXI) treatment
Number of subjects: 568
Study 32462341 — intervention group
Group type: EXPERIMENTAL
Intervention: IO retroequatorial myopexy
Number of subjects: 40
Study 32462341 — intervention group
Group type: COMPARATOR
Intervention: IO myectomy
Number of subjects: 40
Study 35953872 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of intravenous cefazolin (1 g)
Number of subjects: 364
Study 35953872 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 364
Study 33340496 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Number of subjects: 136
Study 33340496 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 136
Study 33340496 — intervention group
Group type: COMPARATOR
Intervention: Inert auricular placebo patches
Number of subjects: 136
Study 35104873 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytical treatment interruptions (ATI)
Number of subjects: 240
Study 35104873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 33135286 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education plus Motor Control Exercises (PNE + MCE)
Number of subjects: 73
Study 33135286 — intervention group
Group type: COMPARATOR
Intervention: Group-Based Exercise (GE)
Number of subjects: 73
Study 33031838 — intervention group
Group type: EXPERIMENTAL
Intervention: LP-Nd:YAG laser
Number of subjects: 150
Study 33407719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine plus ketamine (ketodex)
Number of subjects: 0
Study 33407719 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketamine
Number of subjects: 0
Study 36329796 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Health Choices (IHC) learning resources
Number of subjects: 0
Study 33196487 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobectomy
Number of subjects: 2934
Study 33196487 — intervention group
Group type: COMPARATOR
Intervention: Sublobar resection
Number of subjects: 2934
Study 35710437 — intervention group
Group type: COMPARATOR
Intervention: Usual Care-Plus
Number of subjects: 246
Study 35710437 — intervention group
Group type: COMPARATOR
Intervention: VERSE
Number of subjects: 246
Study 35710437 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 246
Study 32200827 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (topical prednisolone phosphate)
Number of subjects: 106
Study 32200827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 35452873 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 219
Study 34041968 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried bone allograft combined with autograft (Group 1)
Number of subjects: 20
Study 34041968 — intervention group
Group type: COMPARATOR
Intervention: Freeze-dried bone allograft alone (Group 2)
Number of subjects: 20
Study 34041968 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 20
Study 32023184 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric cycling with blood flow restriction (ECCBFR)
Number of subjects: 21
Study 32023184 — intervention group
Group type: COMPARATOR
Intervention: Eccentric cycling (ECC)
Number of subjects: 21
Study 35623879 — intervention group
Group type: EXPERIMENTAL
Intervention: NaBut
Number of subjects: 42
Study 35623879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 33190372 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-containing camouflage
Number of subjects: 30
Study 33190372 — intervention group
Group type: COMPARATOR
Intervention: Blank group (control)
Number of subjects: 30
Study 33070235 — intervention group
Group type: EXPERIMENTAL
Intervention: ACD
Number of subjects: 554
Study 33070235 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 554
Study 32687804 — intervention group
Group type: EXPERIMENTAL
Intervention: BPZE1 vaccine (107, 108, and 109 CFU doses)
Number of subjects: 48
Study 32687804 — intervention group
Group type: EXPERIMENTAL
Intervention: BPZE1 vaccine (all doses)
Number of subjects: 48
Study 32687804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 33269793 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial radiograph for Patient 1 (score 13)
Number of subjects: 2
Study 33269793 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial radiograph for Patient 2 (score 6)
Number of subjects: 2
Study 32051822 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 treatment sessions (group A)
Number of subjects: 102
Study 32051822 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 treatment sessions (group B)
Number of subjects: 102
Study 32051822 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 treatment sessions (group C)
Number of subjects: 102
Study 32051822 — intervention group
Group type: COMPARATOR
Intervention: Comparison between group A and group C
Number of subjects: 102
Study 32051822 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree II nails
Number of subjects: 102
Study 32051822 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree III nails
Number of subjects: 102
Study 35720032 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib combined with bevacizumab
Number of subjects: 84
Study 35720032 — intervention group
Group type: COMPARATOR
Intervention: Albumin‐bound paclitaxel combined with bevacizumab
Number of subjects: 84
Study 34736737 — intervention group
Group type: EXPERIMENTAL
Intervention: CGuard (MicroNet-covered stent)
Number of subjects: 100
Study 34736737 — intervention group
Group type: COMPARATOR
Intervention: Acculink (Conventional stent)
Number of subjects: 100
Study 32070396 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-family therapy (MFT)
Number of subjects: 0
Study 32070396 — intervention group
Group type: COMPARATOR
Intervention: Systemic single-family therapy (SFT)
Number of subjects: 0
Study 35299115 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary carob fruit (CF) supplementation (1 g/kg diet)
Number of subjects: 32
Study 35299115 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 g/kg diet)
Number of subjects: 32
Study 32020852 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35953261 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic retinopexy (PnR)
Number of subjects: 176
Study 35953261 — intervention group
Group type: COMPARATOR
Intervention: Pars plana vitrectomy (PPV)
Number of subjects: 176
Study 32275480 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMS (n=33)
Number of subjects: 62
Study 32275480 — intervention group
Group type: COMPARATOR
Intervention: TAU (n=29)
Number of subjects: 62
Study 32320078 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (CO2 laser treatment followed by three courses of oral traditional Chinese medicine)
Number of subjects: 160
Study 32320078 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO2 laser treatment only)
Number of subjects: 160
Study 32320078 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy group
Number of subjects: 160
Study 32320078 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 32320078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cure group
Number of subjects: 160
Study 35908167 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 24 mg
Number of subjects: 87
Study 35908167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 33605157 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepilex Border Flex (MxBF)
Number of subjects: 51
Study 32640124 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir
Number of subjects: 752
Study 32640124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 752
Study 35508748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal instillation of ropivacaine
Number of subjects: 104
Study 35508748 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 104
Study 34853625 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 179
Study 34853625 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing (non-ERAS)
Number of subjects: 179
Study 33905751 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly exenatide (EQW)
Number of subjects: 14736
Study 33905751 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment in Latin America
Number of subjects: 14736
Study 33905751 — intervention group
Group type: EXPERIMENTAL
Intervention: History of peripheral artery disease
Number of subjects: 14736
Study 33905751 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment in North America
Number of subjects: 14736
Study 33905751 — intervention group
Group type: EXPERIMENTAL
Intervention: History of cardiovascular disease
Number of subjects: 14736
Study 33905751 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous myocardial infarction
Number of subjects: 14736
Study 33255579 — intervention group
Group type: EXPERIMENTAL
Intervention: Labelling lower-energy density (ED) products as healthier choices
Number of subjects: 899
Study 33255579 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the proportion of lower-energy density (ED) products
Number of subjects: 899
Study 33030703 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat 15 mg (single dose)
Number of subjects: 0
Study 33030703 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat 10 mg (once daily)
Number of subjects: 0
Study 33030703 — intervention group
Group type: COMPARATOR
Intervention: Vericiguat 2.5 mg (single or multiple doses)
Number of subjects: 0
Study 33030703 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 0
Study 34973039 — intervention group
Group type: COMPARATOR
Intervention: Prolonged exposure (PE) plus pill placebo (PE+PLB)
Number of subjects: 176
Study 34973039 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus enhanced medication management (SERT+EMM)
Number of subjects: 176
Study 34973039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) plus sertraline (PE+SERT)
Number of subjects: 176
Study 32537238 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term incentives (6 weeks)
Number of subjects: 60
Study 32537238 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term incentives (12 weeks)
Number of subjects: 60
Study 32537238 — intervention group
Group type: COMPARATOR
Intervention: No incentives (control)
Number of subjects: 60
Study 32537238 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care smoking cessation treatment (counseling and nicotine replacement therapy)
Number of subjects: 60
Study 33441772 — intervention group
Group type: EXPERIMENTAL
Intervention: High cut-off (HCO) dialysis
Number of subjects: 19
Study 33441772 — intervention group
Group type: COMPARATOR
Intervention: High-flux (HFL) hemodialysis
Number of subjects: 19
Study 32369032 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate Cancer Screening Preparation (PCSPrep)
Number of subjects: 41
Study 33727066 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 5
Study 33727066 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline plus colchicine
Number of subjects: 5
Study 32980656 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Skills for Life (SSL) intervention group
Number of subjects: 100
Study 32980656 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control (WLC) group
Number of subjects: 100
Study 32500449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed model for repeated measurements (MMRM)
Number of subjects: 0
Study 32500449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern-mixture model
Number of subjects: 0
Study 32500449 — intervention group
Group type: COMPARATOR
Intervention: Statistical methods for imputation
Number of subjects: 0
Study 35090887 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical dry needling plus corticosteroid injection (electrical-DN+CSI)
Number of subjects: 60
Study 35090887 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (CSI)
Number of subjects: 60
Study 32174207 — intervention group
Group type: EXPERIMENTAL
Intervention: PuraStatÂ®
Number of subjects: 20
Study 35653294 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group of obesity (miR-516-3p, miR-130a-3p)
Number of subjects: 38
Study 35653294 — intervention group
Group type: COMPARATOR
Intervention: Low-risk group of obesity (miR-1260b, miR-4709-3p, miR-194-3p)
Number of subjects: 38
Study 33231614 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) dressing
Number of subjects: 60
Study 33231614 — intervention group
Group type: COMPARATOR
Intervention: Normal saline dressing (control group)
Number of subjects: 60
Study 32936795 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to second-line ART
Number of subjects: 80
Study 32936795 — intervention group
Group type: COMPARATOR
Intervention: Continued first-line ART (control group)
Number of subjects: 80
Study 36189591 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM therapy
Number of subjects: 53
Study 36189591 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 53
Study 34530871 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm for identifying patients who may benefit from palliative care review
Number of subjects: 12
Study 34530871 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without the machine learning algorithm)
Number of subjects: 12
Study 35458131 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Ingredient Supplement (MS)
Number of subjects: 24
Study 35458131 — intervention group
Group type: COMPARATOR
Intervention: Caffeine + Guarana (CAF + GUA)
Number of subjects: 24
Study 35458131 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 24
Study 33537776 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS) treatment (2.0 ng/kg)
Number of subjects: 20
Study 33537776 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 34472596 — intervention group
Group type: EXPERIMENTAL
Intervention: aboBoNT‐A solution 50 U
Number of subjects: 0